At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 17, 2026 at 16:30 ET
Evaxion announced two abstracts accepted for presentation at the AACR Annual Meeting, featuring new biomarker and immunogenicity data for its personalized cancer vaccine EVX-01 in melanoma, and preclinical data on using its AI-Immunology™ platform to target glioblastoma. The company will also participate in an industry partnering event, signaling efforts to advance collaborations.
- Two abstracts accepted for AACR 2026 presentation: one on EVX-01 clinical data in advanced melanoma, another on AI-identified neoantigens for glioblastoma.
- EVX-01 data includes durable de novo T-cell responses from a Phase 2 trial combining the vaccine with KEYTRUDA® (pembrolizumab).
- Glioblastoma research is preclinical, focusing on endogenous retrovirus (ERV)-derived neoantigens identified via AI-Immunology™.
- Evaxion will attend the AACR Oncology Industry Partnering event, indicating business development activity.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access